Département de pharmacologie
The research program of Dr Claing aim at studying the molecular mechanisms regulating cellular responses following stimulation of the largest family of trans-membrane receptors, the G protein-coupled receptors. These proteins are the targets of more than 40% of the drugs sold today. The detailed study of the signaling pathways activated by receptors following their stimulation by a broad variety of stimuli ranging from the light to hormones have allowed Dr Claing’s group to reveal the important role of a family of proteins named ADP-ribosylation factors (ARFs). These act like molecular switches to control remodeling of the actin cytoskeleton, transformation of plasma membrane lipids and the process of vesicle formation. Elucidation of the molecular events leading to the activation of ARF proteins as well as the signaling pathways regulated by the GTPases are the main focus of this laboratory. Cellular models used include breast cancer and endothelial cells. The demonstration that ARF proteins are key regulators of intracellular signals activated by membrane receptors will contribute to demonstrate that these proteins are potential new therapeutic targets.
- Poupart ME, Fessart D, Cotton M, Laporte SA, Claing A. ARF6 regulates angiotensin II type receptor endocytosis by controlling the recruitment of AP-2 and clathrin. Cell Signal. 2007 Nov;19(11):2370-8. Epub 2007 Jul 31.
- Cotton M, Boulay PL, Houndolo T, Vitale N, Pitcher JA, Claing A. Endogenous ARF6 interacts with Rac1 upon angiotensin II stimulation to regulate membrane ruffling and cell migration. Mol Biol Cell. 2007 Feb;18(2):501-11. Epub 2006 Nov 22.
- Claing A.: Regulation of G protein-coupled receptor endocytosis by ARF6 GTP-binding proteins. Biochem Cell Biol. 2004 Dec;82(6):610-7. Review.
- Houndolo T, Boulay PL, Claing A.: G protein-coupled receptor endocytosis in ADP-ribosylation factor 6-depleted cells. J Biol Chem. 2005 Feb 18;280(7):5598-604.